EGFR and lung carcinoma: In the case of the 10–15% of lung cancers harbouring epidermal growth factor receptor (EGFR) mutations (in the Caucasian population) and another 3–5% having anaplastic lymphoma kinase (ALK) rearrangements, targeted therapy with erlotinib, gefitinib, or afatinib in the former and with crizotinib in the latter case is recommended.